Last reviewed · How we verify
NCT03771625
Evaluating Structural and Functional Changes of Brain by fMRI and DTI in Patients With Intracranial Germ Cell Tumors
trial testing radiotherapy in Intracranial Germ Cell Tumor in 30 participants. Status unknown.
1 June 2021
Quick facts
| Lead sponsor | Beijing Neurosurgical Institute |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 June 2019 |
| Primary completion | 1 June 2021 |
| Estimated completion | 1 November 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- radiotherapy — full drug profile →
Conditions studied
- Intracranial Germ Cell Tumor — all drugs for Intracranial Germ Cell Tumor →
Sponsor
Beijing Neurosurgical Institute
Who can join
3 and older, any sex, with Intracranial Germ Cell Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BOLD-fMRI and DTI scans are performed to patients with germ cell tumors in the basal ganglia before and after treatments. The changes of the MRI and muscle strength of patients during treatments are evaluated, and the association between these two are investigated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03771625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of radiotherapy
Trials testing the same drug.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07282483 — Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer P · Phase 2 · recruiting
- NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
Other Beijing Neurosurgical Institute trials
Trials by the same sponsor.
- NCT07520214 — Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma · EARLY_PHASE1 · enrolling by invitation
- NCT07285525 — Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS · NA · active not recruiting
- NCT06585527 — Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma · Phase 1 · recruiting
- NCT05803057 — Accelerating Motor Recovering in Patients With SMA Syndrome After Glioma Surgery by Using nrTMS · NA · unknown
- NCT07335029 — Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outco · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03771625 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Neurosurgical Institute
- Last refreshed: 29 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03771625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing